- Study protocol
- Open Access
A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study
BMC Gastroenterology volume 22, Article number: 151 (2022)
Selective internal radiation therapy (SIRT) with yttrium-90 (90Y) resin microspheres is an established locoregional treatment option for unresectable hepatocellular carcinoma (HCC), which delivers a lethal dose of radiation to hepatic tumors, while sparing surrounding healthy tissue. DOORwaY90 is a prospective, multicenter, open-label, single arm study, designed to evaluate the safety and effectiveness of 90Y resin microspheres as first-line treatment in patients with unresectable/unablatable HCC. It is unique in that it is the first study with resin microspheres to utilize a personalized 90Y dosimetry approach, and independent review for treatment planning and response assessment.
Eligibility criteria include unresectable/unablatable HCC, Barcelona Clinic Liver Cancer stage A, B1, B2, or C with a maximal single tumor diameter of ≤ 8 cm, and a sum of maximal tumor diameters of ≤ 12 cm, and at least one tumor ≥ 2 cm (long axis) per localized, modified Response Evaluation Criteria in Solid Tumors. Partition model dosimetry is used to determine the optimal dose; the target mean dose to tumor is ≥ 150 Gy. Patients are assessed at baseline and at regular intervals up until 12 months of treatment for response rates, safety, and quality of life (QoL). Post-treatment dosimetry is used to assess dose delivered to tumor and consider if retreatment is necessary. The co-primary endpoints are best objective response rate and duration of response. Secondary endpoints include grade ≥ 3 toxicity, QoL, and incidence of liver resection and transplantation post SIRT. Target recruitment is 100 patients.
The results of this trial should provide further information on the potential use of SIRT with 90Y resin microspheres as first-line therapy for unresectable HCC.
Clinicaltrials.gov; NCT04736121; date of 1st registration, January 27, 2021, https://clinicaltrials.gov/ct2/show/NCT04736121.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with the third highest solid tumor mortality rate after lung and colon cancer . In the USA, it is estimated that in 2020, 42,810 new cases of HCC were diagnosed, with a 5-year survival rate of 18% . In early-intermediate HCC, liver resection or liver transplantation may be appropriate treatment options , but approximately 70–80% of patients with HCC are not diagnosed early enough to benefit from these potentially curative treatments [4, 5].
Several treatment strategies are available for patients with unresectable HCC. One such strategy is selective internal radiation therapy (SIRT), also referred to as radioembolization. SIRT is a technique that selectively deposits yttrium-90 (90Y) microspheres into the hepatic vasculature to deliver a lethal dose of radiation to the tumor(s). Surrounding healthy liver tissue can be spared by selectively delivering the microspheres into specific Couinaud segment(s) or the tumor vasculature itself. SIRT exploits the tumor’s hypervascularity relative to healthy tissue, delivering safe levels of radiation to normal tissue while achieving a selective tumoricidal dose. Relative to bland embolization or chemoembolization, SIRT minimizes potential macroembolic effect. Instead, SIRT leads to partial occlusion (microembolization) of the vascular supply to the tumor while the beta-radiation emitted from 90Y induces DNA damage in tumor cells [6, 7].
SIRT has the potential to not only delay local progression but also to downstage the disease to allow resection or transplantation if the disease meets Milan, or similar, criteria [8,9,10]. Previous randomized clinical trials of first-line 90Y resin microspheres (SIR-Spheres®, Sirtex Medical) for advanced HCC did not meet their primary endpoints for a number of reasons that include: (1) inadequate dosimetry-treatment planning; (2) poorly controlled patient populations; and (3) no post-treatment confirmation of absorbed dose [11,12,13]. These trials were initiated and conducted before the development of our current understanding of radiation-dose–response following SIRT, and before the widespread acceptance of personalized dosimetry for SIRT .
To overcome the limitations of these trials, we initiated the Duration Of Objective Response with arterial Yttrium-90 (DOORwaY90) study of 90Y resin microspheres, which utilizes a personalized dosimetry approach using the partition model and is recruiting patients with unresectable HCC (Barcelona Clinic Liver Cancer [BCLC] stage A, B1, B2 and C). All eligible patients receive 90Y resin microspheres using either a selective or lobar approach.
The DOORwaY90 trial is a pivotal, prospective, multicenter, open-label, single-arm study. The objective is to evaluate the safety and effectiveness of 90Y resin microspheres as first-line treatment for unresectable HCC (BCLC stages A, B1, B2, and C).
All relevant institutional and local ethics committee approvals were gained before commencing the study (Additional file 1). The study is being conducted in 14 investigational sites in the USA and aims to enroll approximately 100 patients (Fig. 1). No single site will enroll more than 20% of the study population. Written informed consent is obtained from all participants (or their legally authorized representatives) prior to participation in this study.
Investigators and study sites are required to permit study-related monitoring, audits, Institutional Review Board (IRB) review, and regulatory inspection(s) and provide direct access to source data/documents. This study will have oversight by a Data and Safety Monitoring Board (DSMB), which will review summarized safety data (including enrollment, protocol deviations, and adverse events) and will use stopping rules as defined in the DSMB Charter. The sponsor may also terminate or suspend the study if the DSMB stopping rules have been met. Sites must submit any protocol amendments to the IRB and are required to forward a copy of the written approval to the CRO. The final dataset will be available to the sponsor/CRO and IRB.
Important aspects of the trial include: (1) personalized dosimetry for treatment planning; (2) centralized review of the treatment plans and verification scans; (3) use of an independent core laboratory for response assessment; (4) a specific patient population that would benefit from locoregional treatment; (5) potentially curative treatment; (6) confirmation of absorbed dose delivered to the tumor; and (7) assessment of long-term toxicity.
Adult (≥ 18 years of age) patients enrolled into this study have a diagnosis of HCC BCLC stage A, B1, B2, or C with a maximal single lesion size of ≤ 8 cm and a sum of maximal tumor diameters of ≤ 12 cm, with the entire tumor burden expected to be treatable within the perfused volume. Patients cannot be considered suitable for treatment by resection or ablation at the time of study entry. For safety considerations, ≥ 33% of the total liver volume (body surface area-based) must be disease free and not treated with 90Y . All inclusion and exclusion criteria are summarized in Table 1.
The methods of catheter angiography and hepatic arterial mapping for SIRT are well established and reviewed elsewhere . Briefly, angiography is performed to identify the appropriate catheter position for administration of the microspheres and to visualize any hepatic or gastrointestinal vessels that may result in non-target dose deposition. If found, these vessels must be successfully circumvented before proceeding with SIRT, either by adjusting the catheter placement or by performing prophylactic embolization. After this evaluation, technetium-99m (99mTc)-macroaggregated albumin (MAA) is administered via the catheter at the planned treatment position as a surrogate for the 90Y microspheres. The biodistribution of the 99mTc-MAA is assessed via planar scintigraphy of the chest and abdomen and single photon emission computed tomography/computed tomography (SPECT/CT) of the liver.
Target and non-target tumor compartments and the treated non-tumoral liver tissue compartments are segmented, and volumes and 99mTc-MAA uptake determined. The patient-specific target tumor-to-normal ratio (TNR) that is needed as input for the partition model is then calculated. The catheter tip during 99mTc-MAA injection would typically be placed at the same anatomical position from which 90Y resin microspheres will be administered. The exception is when segmental treatments are planned, in which case, lobar 99mTc-MAA injection may be performed, at the discretion of the clinician. When a segmental treatment (number of segments ≤ 2) is planned, the TNR value is then set to 1.0 (i.e., plan as a single compartment), and the minimum planned dose to the segment is > 150 Gy. Multi-vessel treatments are permitted. However, a cone-beam computed tomography (CBCT) or in-room fan beam CT should be performed to adequately determine the perfused volume. 99mTc-MAA is administered at each location; exceptions include segmentectomy cases. Clinical justification for adjustment or alteration of catheter position between sessions is documented. All pre-SIRT images and contours are assessed jointly by the treatment physician and the Eligibility Review Committee to confirm treatment planning dosimetry and approach based on the dosimetry principles and constraints outlined next.
Treatment plan dosimetry
CBCT or in-room fan beam CT is used for volume calculation. 3D volumetric software is used to segment the total liver volume (TLV), the volume of perfused normal liver parenchyma (NLp) and the treated tumor (TT) compartments in the liver, and to determine their volume (in ml) and the total 99mTc-MAA counts in the NLp and TT compartments. Soft-tissue density of 1.06 g/ml is used to determine the mass (in kg) of the TT compartment (Mtumor) and the mass of the perfused normal liver compartment (MNLp). The patient-specific tumor uptake ratio, R, is calculated (using MIM Maestro) as:
R = tumor compartment (total 99mTc-MAA counts/total volume of interest)/perfused normal liver compartment (total 99mTc-MAA counts/total volume of interest)
Based on partition model equations , the administered activity (Aadmin) required to meet the intended mean dose to the tumor compartment, Dtumor, is calculated according to the formula:
Aadmin [GBq] = Dtumor [Gy] × Mtumor [kg]/(49.7 [Gy-kg/GBq] × (1-LSF) × R × Mtumor/(MNLp + R × Mtumor)), where LSF is the lung shunt fraction.
The mean dose to the perfused normal liver compartment, DNLp, is calculated as:
DNLp [Gy] = Dtumor [Gy]/R.
Regions of interest are drawn around the lung region and the liver region in both the anterior and the posterior views of planar scintigraphy. The view with the highest 99mTc-MAA counts for the liver region is used to determine the 99mTc-MAA counts in the lung region and the 99mTc-MAA counts in the liver region for the calculation of the lung shunt fraction (LSF). The LSF is calculated using the following formula:
LSF = (counts in lung region)/((counts in lung region) + (counts in liver region))
The mean lung dose (Dlung) corresponding to a specific LSF can be determined as:
Dlung [Gy] = Aadmin [GBq] × LSF × 49.7 [Gy-kg/GBq]/Mlung [kg], where Mlung is the mass of lung tissue [kg].
The Mlung can be calculated using a patient-specific CT scan or can be estimated as 1 kg.
Treatment plan dosimetry constraints
Normal liver constraints: patients are excluded if < 33% of the total liver volume based on body surface area (TLVBSA) is tumor free, and therefore, left untreated. The TLVBSA is calculated based on the method of Vauthey et al.  as:
TLVBSA [ml] = − 794.4 + 1267.3 × (height [cm] × weight [kg]/3600)0.5
If the 90Y treatment-spared liver volume is ≥ 33% but < 40% of the TLVBSA, the dose to the perfused normal liver parenchyma will be limited to < 150 Gy . If the 90Y treatment-spared liver volume is ≥ 40% of the TLVBSA, there will be no upper limit to the dose allowed to the perfused normal liver parenchyma .
Lung mean dose (Dlung) constraints: Dlung ≤ 30 Gy for a single treatment, and the cumulative lung mean dose < 50 Gy if the patient is re-treated.
Tumor mean dose (Dtumor) constraints: the planned mean dose to the tumor must be in the range of 150–400 Gy. The lower limit of 150 Gy was based on the estimated mean dose required to achieve a complete response (CR) in previous studies [19, 20]. In the unlikely event that the planned mean dose to the total tumor compartment cannot exceed 150 Gy, the patient is considered a screening failure.
All treatments are performed with 3-day FLEXdose delivery option in a single treatment session using a selective or lobar approach. To optimize the predictive value of the 99mTc-MAA intra-hepatic distribution, the catheter tip during 99mTc-MAA injection is recommended to be placed at the same anatomical position from which 90Y resin microspheres will be administered (a deviation greater than ± 0.5 cm is allowed, if necessary, but must be documented; likewise, the occurrence of stasis will be documented).
After the SIRT procedure
Post-treatment assessment is conducted by imaging of the patient’s abdomen with 90Y SPECT/CT or 90Y PET/CT. Post-SIRT images are assessed by the Eligibility Review Committee using FDA-approved software to qualitatively confirm tumor targeting, quantify the mean tumor dose delivered, and to decide if re-treatment may be necessary.
If the mean tumor dose delivered, based on post-treatment 90Y SPECT/CT or 90Y PET/CT imaging, was estimated to be < 100 Gy, SIRT re-treatment may be performed at the discretion of the treating physician within 4 weeks of the index procedure.
Treated patients will be assessed at baseline (no more than 28 days before SIRT), and at 1, 2, 4, 6, 9 and 12 months (± 2 weeks) and at 24 months (± 1 month) after SIRT. All patients are assessed according to the schedule summarized in Table 2. All images used to assess tumor response are reviewed at an independent centralized laboratory (American College of Radiology Center for Research and Innovation, Philadelphia, PA; ACR). Patients may be withdrawn from the study due to loss of follow-up, death, withdrawal of consent, adverse events, investigator decision, or if there is failed SIRT implantation. If a patient withdraws from the study a study completion electronic case report form must be completed, describing the reason for discontinuation. After 24 months and exit from the study, patients will be assessed and managed as per usual care.
The co-primary endpoints are localized objective response rate (ORR; CR or partial response [PR]) using modified Response Evaluation Criteria in Solid Tumors (mRECIST)  with best response through 9 months, and duration of response (DoR), defined as the time-interval from first achieving a response (i.e., CR or PR) until disease progression (≥ 6 months for ≥ 60% of responders).
Secondary endpoints include: grade ≥ 3 toxicity (Common Terminology Criteria for Adverse Events, CTCAE v5.0) at 3 months and 6 months; quality of life (QoL) measured by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire and the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L); liver resection rate; and liver transplant rate.
Sample size calculation and statistical considerations
Continuous data will be summarized using descriptive statistics: sample size, mean, standard deviation, standard error, median, and range or interquartile range. Discrete variables will be summarized using frequency counts and percentages. All statistical analyses will be performed using SAS (version 9.4 or higher, SAS Institute Inc. Cary, NC), R (version 3.2 or higher, R Foundation for Statistical Computing, Vienna, Austria) or other widely accepted statistical or graphical software.
Primary analyses will be conducted under the principles of intent-to-treat (ITT), using the full analysis set (FAS) as defined in ICH E9 (Statistical Principles for Clinical Trials). Additionally, a per-protocol (PP) population is defined, including ITT patients who met all inclusion and exclusion criteria, received the intended dose of 150–400 Gy, and had no major protocol violations.
Methods for replacing missing data such as last value carried forward or multiple imputation will not be routinely used for the primary study analyses. For the purposes of defining the primary endpoints, death before the first attempt at evaluation will be defined as failure of the endpoint in question, and if no evaluable mRECIST data are collected for a patient, they will be classified as a failure for the ORR endpoint and as missing data for the DoR endpoint. Planned subgroup analyses will be conducted to evaluate consistency of results by gender and dosimetry method. Additionally, a dose–response analysis will be conducted to estimate the threshold mean tumor dose for response for tumors ≥ 3 cm. For the co-primary endpoint ORR, all lesions in the treated portion of the liver will be included for analysis, with up to 2 lesions per patient defined as target lesions and the rest non-target lesions. ORR results will be presented as the proportion of successes (CR or PR) with corresponding confidence limits calculated by the exact binomial (Clopper-Pearson) method. The performance goal is a lower confidence interval for best response on ORR of 40%. A DoR of ≥ 6 months in ≥ 60% of responding patients is the goal of the co-primary endpoint.
An overall summary of adverse events (AEs) will be presented, which will include the number and percentage of patients with at least one AE, and the total number of AEs. All AEs will be adjudicated by a Clinical Events Committee (CEC). AEs will additionally be classified according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary, summarized by severity, relationship to SIRT, outcome and seriousness. Serious adverse events (SAEs) will be summarized according to severity and relationship. Multiple occurrences of the same AE are counted once at the maximum grade and strongest relationship, as appropriate.
The postulated success rate for the ORR primary endpoint is estimated to be 55–60% based on previous experience with the study device and expert opinion on its effectiveness in the target population; as stated, the performance goal applied to the lower confidence bound for this estimate is 40%. Given a two-sided test at an alpha of 0.05 and desired power of 80%, the required evaluable sample size using the exact method for a single proportion and the worst estimate above is no greater than 90. Therefore, a study sample size of 100 is targeted to provide adequate powering for hypothesis testing as described above. Consent from up to 150 patients is anticipated to achieve the sample size of 100 patients, based on previous experience of eligibility failure of 33%. The overall study duration, from screening the first patient to the final follow-up visit, data analysis and final report, is expected to be approximately 39 months.
The DOORwaY90 trial will provide clinically relevant and novel information on the effectiveness and safety of 90Y resin microspheres for the treatment of unresectable HCC when personalized dosimetry methods are used. Previous large trials of SIRT with 90Y resin microspheres have not used personalized dosimetry [11,12,13], and subsequent analyses have suggested that sub-optimal doses have been used in these trials, resulting in sub-optimal effects of SIRT [19, 22]. A recent trial using personalized dosimetry with 90Y glass microspheres further emphasized the need for a personalized approach to SIRT dosimetry to achieve optimum results . However, because of differences in the size, distribution, and specific activity of glass and resin microspheres, dosimetry findings cannot be translated from one product to the other, and therefore, the DOORwaY90 trial is needed to provide information on the impact of personalized dosimetry on the efficacy of 90Y resin microspheres.
The delivered mean tumor dose of < 100 Gy to trigger possible SIRT re-treatment is 66% of the minimum target tumor dose. This cut-off was used partly because there is an error of at least 20% in quantifying post-SIRT 90Y SPECT/CT or 90Y PET/CT-based tumor doses . Furthermore, an average tumor dose of 110 Gy has been shown to result in tumor response in > 50% of patients (according to RECIST; and according to EASL guidelines, response was achieved in > 70% of patients) . Therefore, the mean tumor dose cut-off of 100 Gy should avoid unnecessary SIRT re-treatment.
There is increasing evidence that SIRT may have the potential to downstage unresectable HCC, or act as a bridge to transplantation. This needs investigation in dedicated clinical studies, but the DOORwaY90 trial includes patients with earlier stage HCC than in previous prospective trials of 90Y resin microspheres and may help provide further insight into the ability of SIRT to convert patients to resectability. The DOORwaY90 trial further offers the opportunity to assess the safety profile of 90Y resin microspheres in the US population—an important consideration as many systemic treatments for HCC have safety profiles that can adversely impact patient QoL.
The DOORwaY90 study design is unique for several reasons. The DOORwaY90 study is the first prospective, multicenter US trial to utilize personalized 90Y dosimetry with 90Y resin microspheres: the use of a patient-specific target TNR allows a personalized prescribed activity that results in a dose that achieves maximum damage to the tumor, with minimal damage to healthy tissue. It is also the first study to employ an Eligibility Review Committee to determine patients’ treatment plans. In addition, unlike previous studies, tumor responses will be evaluated by an independent review body (ACR), and using novel imaging software (MIM Sureplan) we will assess if tumors achieve a minimum threshold dose to determine if patients are eligible for early retreatment. This study also utilizes a well-controlled patient population with a well-defined safety margin. The FLEXdose delivery program for 90Y resin microspheres ensures that all sites are using the same activity per sphere, that increases confidence in the entire planned activity being delivered without the potential for unplanned stasis (the 3-day FLEXdose delivery option also reduces further any risk of a macroembolic effect). The co-primary endpoints of ORR and DoR used in the DOORwaY90 trial were chosen as a measure of local disease control. As SIRT is a locoregional therapy, assessment of local disease control is a more relevant measure of effectiveness than overall survival.
The results of the DOORwaY90 trial will help refine the potential benefits of SIRT with 90Y resin microspheres as first-line therapy for HCC and may strengthen future consensus guidelines. If the DOORwaY90 trial meets its co-primary endpoints, personalized SIRT may become a new standard of care for patients with unresectable HCC. Such a treatment has the potential to facilitate liver resection or transplantation, and a consequent increased life expectancy and enhanced QoL for these patients.
Availability of data and materials
Not applicable for this publication. In future, it is our intention that results will be fully disclosed in ClinicalTrials.gov, by presentation at international congresses and via publication in a peer-reviewed journal.
Barcelona Clinic Liver Cancer
Cone-beam computed tomography
Clinical Events Committee
Contract research organization
Common terminology criteria for adverse events
Duration of response
Data and Safety Monitoring Board
The European Association for the Study of the Liver
Five-level EuroQol five-dimensional questionnaire
Functional Assessment of Cancer Therapy-Hepatobiliary
Institutional Review Board
Intent to treat
Lung shunt fraction
Medical Dictionary for Regulatory Activities
Objective response rate
Quality of life
Modified Response Evaluation Criteria in Solid Tumors
Serious adverse events
Selective internal radiation therapy
Single photon emission computerized tomography
- TLVBSA :
Total liver based on body surface area
Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma—a multidisciplinary approach. Int J Mol Sci. 2019;20:1465.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23:5282–94.
El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158–66.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–63.
Arii S, Teramoto K, Kawamura T. Current progress in the understanding of and therapeutic strategies for ischemia and reperfusion injury of the liver. J Hepatobiliary Pancreat Surg. 2003;10:189–94.
Birgin E, Rasbach E, Seyfried S, Rathmann N, Diehl SJ, Schoenberg SO, et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with (90)Y-microspheres: a systematic review. Cancers (Basel). 2020;12:294.
Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP, Tai DW, et al. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery. 2018;163:1008–13.
Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stubs P, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59:1864–73.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36.
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21.
Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164–74.
Levillain H, Bagni O, Deroose CM, Dieudonne A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48:1570–84.
Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8:233–40.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92.
Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947–52.
Hsieh CE, Venkatesulu BP, Lee CH, Hung SP, Wong PF, Aithala SP, et al. Predictors of radiation-induced liver disease in Eastern and Western patients with hepatocellular carcinoma undergoing proton beam therapy. Int J Radiat Oncol Biol Phys. 2019;105:73–86.
Hermann A-L, Dieudonne A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 in the SARAH study. Radiology. 2020;296:673–84.
Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377–85.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1662-70 e4.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29.
Willowson KP, Tapner M, Team QI, Bailey DL. A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : the QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42:1202–22.
Martin Gilmour and Elisabeth Jane Meredith of Empowering Strategic Performance (ESP) Ltd, Crowthorne, UK provided medical writing and editorial support, which was sponsored by Sirtex Medical in accordance with Good Publication Practice guidelines.
DOORwaY90 is funded, organized and conducted by Sirtex Medical in accordance with Good Clinical Practice Guidelines.
Ethics approval and consent to participate
All relevant institutional and local ethics committee approvals were gained before commencing the study. A full list of institutional review board (IRB) approvals is supplied in the Additional file 1. Written informed consent is obtained from all participants (or their legally authorized representatives) prior to participation in this study. Consent will be obtained by the investigator. All data used in the analysis and reporting of this study will be without identifiable references to a participant.
Consent for publication
AM has acted as a consultant and received research support from Sirtex, BTG/Boston Scientific, Siemens Healthineers and ABK Biomedical. SC, MT, PH, and SG are employees of Sirtex Medical. SB is an employee of Bright Research Partners and has acted as a consultant to Sirtex. SCK has acted as a consultant to Sirtex and ABK Medical, and has received research support from Boston Scientific, ABK Biomedical and GE Healthcare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mahvash, A., Chartier, S., Turco, M. et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol 22, 151 (2022). https://doi.org/10.1186/s12876-022-02204-1
- 90Y resin microspheres
- Hepatocellular carcinoma (HCC)